Contact this trialFirst, we need to learn more about you.
Glucagon-like peptide-1 (GLP-1) receptor agonist
Tirzepatide for Obesity
Recruiting2 awardsPhase 3
Brampton, Ontario
This trial is testing two weight-loss medications, tirzepatide and semaglutide, in adults who are obese or overweight with health issues related to their weight but do not have Type 2 Diabetes. These medications help reduce appetite and make people feel full sooner, which can lead to weight loss. Semaglutide has been shown to promote significant weight loss and improve health conditions related to obesity.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service